China
Africa
Explore chapters and articles related to this topic
Prevention and Treatment of Adverse Effects of Antineoplastic Therapy and of Delayed-Onset Side Effects: Prevention and Treatment of Hair Loss
Published in Paloma Tejero, Hernán Pinto, Aesthetic Treatments for the Oncology Patient, 2020
There have been trials with some prevention measures: the use of tempol, vitamin D3, and prostaglandins E2. It is believed that they would have a protective effect against radiotherapy-induced alopecia. However, there are still no totally effective methods to prevent alopecia by radiation [29,32]. In all patients, it is very important to ensure strict photoprotection of the hairless area by means of caps, handkerchiefs, and/or sunscreen products. In cases of permanent alopecia, reconstructive surgery or hair transplantation may be used in selected patients.
Actions of Dopamine on the Skin and the Skeleton
Published in Nira Ben-Jonathan, Dopamine, 2020
Alopecia refers to loss of hair from part of the head or body. The severity of hair loss can vary from a small area to the entire body [45,48]. Alopecia is an autoimmune skin disease that affects as many as 6.8 million people in the United States, with a lifetime risk of 2.1%. People of all ages, both sexes and all ethnic groups can develop the disease. Alopecia often first appears during childhood and can be different for various individuals. The causes that trigger the immune system to attack healthy hair follicles are not clear but could be internal (virus or bacteria), due to stress, or environmental. Some medications, including chemotherapy, HIV/AIDS, hypothyroidism, and malnutrition (e.g., iron deficiency), can also cause hair loss. The causes of hair loss accompanied by scarring or inflammation include fungal infection, lupus erythematosus, radiation therapy, and sarcoidosis. Diagnosis of hair loss is partly based on the areas affected. Common interventions include medications such as minoxidil and hair transplant surgery.
Disorders of hair and nails
Published in Ronald Marks, Richard Motley, Common Skin Diseases, 2019
Congenital alopecia may occur in isolation or with other congenital disorders. Rarely, scalp hair growth is very slow and hair shaft density is low (congenital hypotrichosis). A patch of scarring over the vertex with hair loss is another, uncommon, type of congenital alopecia.
Preparation and optimization of aloe ferox gel loaded with Finasteride-Oregano oil nanocubosomes for treatment of alopecia
Published in Drug Delivery, 2022
Khaled M. Hosny, Waleed Y. Rizg, Eman Alfayez, Samar S. Elgebaly, Abdulmohsin J. Alamoudi, Raed I. Felimban, Hossam H. Tayeb, Rayan Y. Mushtaq, Awaji Y. Safhi, Majed Alharbi, Alshaimaa M. Almehmady
Alopecia is a common disorder that results in hair loss in one or more areas of the body. This condition can manifest in a variety of ways depending on the severity and area affected, ranging from isolated or multiple small patches (Alopecia areata) to a diffuse hair loss on the scalp (Alopecia totalis) or on the entire body skin (Alopecia universalis) (Alopecia universalis) (Amin & Sachdeva, 2013; Safavi et al., 1995). Any hair-bearing area could be impacted by Alopecia, but the scalp is the most prominent part. Alopecia affects 2% of population with no perceivable difference between men and women (Lee et al., 2020). Despite the fact that the underlying causes of Alopecia remain an unknown, several studies have suggested that environmental, immunologic, and genetic factors may play a role in its progress (Darwin et al., 2018). Furthermore, the relationship between the microbial population that inhabits the scalp and hair growth abnormalities such as Alopecia areata (AA) has recently been the focus of attention among researchers and clinicians (Constantinou et al., 2021). It has recently been established that the bacteria Propionibacterium acnes is involved in the pathogenesis of AA (Wang et al., 2012).
Preparation of topical bimatoprost with enhanced skin infiltration and in vivo hair regrowth efficacy in androgenic alopecia
Published in Drug Delivery, 2022
Laxman Subedi, Prashant Pandey, Jung-Hyun Shim, Ki-Taek Kim, Seung-Sik Cho, Kyo-Tan Koo, Beum Joon Kim, Jin Woo Park
Alopecia refers to abnormal hair loss, typically accompanied by a change in the normal hair growth cycle (i.e. shortened anagen phase and prolonged catagen and telogen phases) (Qi & Garza, 2014). A variety of factors are associated with changes in the hair cycle, including hormonal imbalances, aging, autoimmune conditions, medications, nutritional deficiencies, and genetics (Houschyar et al., 2020). Although alopecia does not have severe physical symptoms, it does have significant adverse psychological and social effects (Saceda-Corralo et al., 2018). Therefore, treatment of alopecia is necessary to maintain the well-being of patients. Hair transplants and injection of growth factors and platelet-rich plasma are increasingly being used for alopecia patients, but have poor efficacy and the potential for various complications (Kerure & Patwardhan, 2018; Ro In et al., 2021). Treatments for alopecia aim to normalize the hair follicle size, density, and growth cycle.
Tolerability of hair cleansing conditioners: a double-blind randomized, controlled trial designed to evaluate consumer complaints to the U.S. Food and Drug Administration
Published in Cutaneous and Ocular Toxicology, 2020
Erin M. Warshaw, Jamie P. Schlarbaum, Yujie L. Liou, Rebecca S. Kimyon, Amy J. Zhang, Anne B. Nikle, Andrew D. Monnot, Sara A. Hylwa
Are individuals with pre-existing hair/scalp conditions more likely to use WCD HCCs (epidemiologic confounder)? This is unclear. Medical problems such as “dermatologic conditions” (44% of FDA claimants4, 4.1% of 512 individual self-reports60) and/or “hormonal imbalances” (6% of FDA claimants4, 3.1% of 512 individual self-reports60) may be associated with alopecia. Unfortunately, photographs are sparse and those provided are consistent with alopecia areata, telogen effluvium, or female-pattern hair loss20,65. Time to symptom onset in the 512 individual self-reports varied from ≤1 month (28%) to 2–6 month (36%) and >6 months (36%, including 13% >2 years)60, indicating no obvious clustering. It is also important to underscore the subjective nature of non-scarring alopecia; it is estimated that up to 30% of patients seen in alopecia clinics have no demonstrable cutaneous findings; in these cases, symptoms are categorized as body dysmorphic/somatoform pain syndromes66. This complicates any analysis of patient-reported alopecia without objective scientific evaluations by dermatology experts.